Disclosure of Information

RNS Number:1962C
Biofusion PLC
16 August 2007


For immediate release                                            16 August 2007


                                 BIOFUSION PLC

                         ("Biofusion" or "the Company")


                                  AIM Rule 26



Biofusion plc (AIM: BFN), the university IP commercialisation company that turns
world class research into business, confirms that the relevant AIM Rule 26
information may be found on the Company's website at www.biofusion.co.uk



For further information about Biofusion, please contact:


Biofusion
David Baynes / Stuart Gall                                  +44 (0) 114 275 5555

Buchanan Communications
Lisa Baderoon / Mary-Jane Johnson / Catherine Breen          +44 (0)20 7466 5000





About Biofusion

Biofusion was established in 2002 to commercialise university-generated IP.
Biofusion has signed long term agreements with two of the UK's top ten research
intensive universities (University of Sheffield and Cardiff University) giving a
combined R&D spend attributable to Biofusion of approximately #114 million a
year. The Company has a portfolio of 23 spin-out companies.

Biofusion's first agreement was a ten-year exclusive arrangement with the
University of Sheffield for the commercialisation of IP owned by the University
in the area of medical life sciences. Biofusion has shareholdings in a portfolio
of 16 Sheffield University spin-out companies including Asterion, Axordia,
Celltran, Lifestyle Choices, Diurnal and Phase Focus. The University of
Sheffield was ranked 5th in the UK for the quality of its life sciences research
and will be spending an estimated #0.5bn of research funding over the lifetime
over the life of the Sheffield Agreement.

In January 2007, Biofusion completed a long-term exclusive agreement with
Cardiff University, to commercialise 100% of all Cardiff University's
research-generated IP.  Biofusion has shareholdings in a portfolio of seven
Cardiff University spin-out companies including Abcellute, Q-Chip and Cardiff
Protides. Cardiff University was ranked 7th in the UK in the most recent
research rankings and will be spending over #1.0bn of research funding over the
lifetime over the life of the Cardiff Agreement.






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCGUUQPRUPMGMA

Biofusion (LSE:BFN)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024